A commercial organization wants to know whether its field activity changed prescribing behaviour. That is not observable. What exists is syndicated data that was sampled, projected and delivered weeks late, activity data your own systems recorded about themselves, and a set of assumptions connecting the two. Analytics that acknowledges this is useful. Analytics that presents the inference as a measurement gets found out in the first quarter it is wrong.
We build the commercial and operational analytics layer for pharmaceutical, biotechnology and research organizations: syndicated prescription and claims data integrated with CRM, ERP, finance, supply chain and patient services, modelled against territory and product hierarchies that change, delivered through dashboards and semantic models that are governed rather than merely built. The engineering is the straightforward part. The work that determines whether anybody uses the result is deciding what each number means, who is permitted to see it at what grain, and what the number is actually evidence of.
Commercial analytics in Life Sciences is unlike commercial analytics in almost any other industry, and the difference is not complexity. It is that the transaction you care about happens between a prescriber and a patient, in a room you cannot see into, and is reported back to you by a third party who sampled it. Prescription and claims data arrives projected from a panel to a universe, aggregated to a level that privacy rules and vendor contracts permit, and delivered on a lag that is sometimes a week and sometimes a month. Your own CRM tells you what your field force recorded about its own activity. Your ERP tells you what shipped to a wholesaler, which is not what a patient took.
None of that makes commercial analytics impossible, and all of it makes the discipline different. The organization is reasoning about causality with no way to run a clean experiment, comparing periods across territory structures that were redrawn, and reconciling systems that each describe a different part of the same commercial event. The analytics teams that are trusted state what each number is evidence of and what it is not. The ones that are not trusted built a dashboard where every figure looks equally solid.
The commercial truth is purchased
Projected from a sample, aggregated by contract, delivered late, and treated internally as fact.
Attribution cannot be run as an experiment
No holdout territory, no clean control, and a number is still required by Thursday.
Market share has at least four definitions
And two functions are using different ones in the same meeting.
Territory realignment breaks every historical trend
Unless history was restated under the new alignment, which it usually was not.
Shipments are counted as demand
Wholesaler inventory movement is reported as patient uptake and the forecast inherits the error.
Access rules are bolted on after the model is built
When HCP privacy and vendor contracts dictate the grain the model should have had.
Self-service was given to people without governed definitions
And now there are nine versions of the same KPI, all technically correct.
Ask what each number on the executive dashboard is evidence of. Take the dashboard your commercial leadership looks at weekly and go figure by figure, asking what each one is actually evidence of, what it is being used to decide, and how it would behave if the underlying assumption were wrong. Shipment data presented as demand. A rep-level share figure carrying projection error nobody quantified. A year-on-year comparison spanning a realignment. An activity metric measuring whether an interaction was logged rather than whether it occurred. Most dashboards survive this exercise with two or three figures that should carry a caveat and do not, and those are usually the figures driving the most expensive decisions.
The order matters more than the list. Defining the measures comes before building the model, because a semantic model built on undefined KPIs encodes the ambiguity permanently and then distributes it to everybody with a Power BI licence. Access design comes before the model is published rather than after, because privacy and vendor contract restrictions determine what grain the model may expose. And the forecast is built last, on data whose limitations are already documented, rather than first on data nobody has examined.
Step 1
Assess the decisions, not the data
Step 2
Define the measures and give each one an owner
Step 3
Integrate syndicated, CRM, ERP and operational sources
Step 4
Model the hierarchies, including their history
Step 5
Analyze with the confounders stated
Step 6
Visualize for a decision, not for coverage
Step 7
Forecast with the assumptions visible
Step 8
Govern definitions, access and certification
Step 9
Automate the refresh and the reconciliation
Step 10
Operationalize ownership, adoption and cost
One definition, one owner, one certified dataset. The most valuable deliverable in a commercial analytics programme is often not a dashboard. It is a short document listing the measures leadership acts on, with one agreed definition each, the owner who approves changes to it, the certified dataset it comes from, and the known limitations of the underlying data. It takes weeks rather than months, it requires decisions rather than engineering, and it is the thing that stops the meeting where two functions present different numbers for the same quarter. Build it before the semantic model, because the model will encode whatever ambiguity is left.
Grouped by the decision each supports rather than by technology. Most organizations need a subset, and the sequencing usually matters more than the scope: the measures and hierarchies have to be right before the forecasting and the self-service layer are worth building.
See
Commercial analytics across syndicated, CRM and internal sales data
Sales performance analytics at national, regional, territory and account level
Market intelligence, competitive share and market definition management
Customer and HCP analytics within the applicable privacy and consent constraints
Territory and field force analytics, including alignment history and coverage
Product performance and launch tracking against defined uptake expectations
Executive dashboards built for recurring decisions and named audiences
Explain
Revenue analytics across gross to net, channel and contract performance
Promotional response analysis with confounders stated and methods documented
Market access, formulary coverage and payer mix analytics
Pricing and contract analytics, including rebate and chargeback visibility
Patient services and hub analytics where permitted by consent and privacy terms
Financial analytics tied to the same certified measures as the commercial views
Anticipate
Demand forecasting with consumption separated from shipment and inventory movement
Forecast accuracy monitoring against prior forecasts, by product and horizon
Predictive models for prioritization, with the limits of the training data documented
Operational analytics across manufacturing, supply chain and inventory performance
Enterprise performance management linking commercial, operational and financial measures
Govern
KPI definition management with named owners and controlled change
Semantic models with certified measures and labelled variants
Role, territory and contract based access resolved at query time
Self-service enablement with governed definitions and a certified dataset boundary
Decision intelligence: each view tied to a decision, an owner and an action
The common thread across these is that each one is a recurring decision somebody is already making, usually with data assembled by hand. The value is rarely in a capability nobody had. It is in the same decision being made faster, from numbers the next function up does not dispute.
| Function | The decision | What the analytics has to get right |
|---|---|---|
| Pharmaceutical commercial operations | Where to deploy field effort next cycle | Territory alignment history, projection error at small units, target list versioning |
| Biotechnology commercialization | Whether a first commercial launch is tracking | Few comparators, short history, and uptake expectations set before launch rather than after |
| Product launch analytics | Whether to adjust investment in the first three quarters | Early signals separated from noise, and shipment movement separated from patient uptake |
| Sales and marketing effectiveness | Where promotional investment is producing a return | Confounders named, method documented, and a range rather than a single attribution figure |
| HCP engagement | Which interactions are worth the next cycle | Consent and opt-out status honoured, and interaction data that reflects what occurred |
| Market access | Where coverage is limiting uptake | Payer and formulary data aligned to the same geographies as the prescribing data |
| Pricing and contract analytics | Whether a contract is performing as modelled | Gross to net clarity, rebate and chargeback timing, and contract terms held as data |
| Patient services | Where patients are dropping out of the access journey | Strict consent scope, and hub data kept within its permitted use |
| CRO operations | Whether study delivery is on plan across a portfolio | Operational data by study and sponsor, with contractual separation enforced |
| Clinical trial operations | Where enrolment and data flow are falling behind | Operational metrics only, and a firm boundary against commercial data |
| Manufacturing and supply chain | Where to adjust production and distribution | Batch, site and plant data, and demand signals distinguished from order patterns |
| Inventory | Whether channel inventory is masking real demand | Wholesaler and channel inventory visibility, and consumption modelled rather than assumed |
| Enterprise performance management | Whether commercial, operational and financial views agree | One certified set of measures used by all three, with reconciliation that is visible |
Commercial analytics architectures tend to be judged on the pipeline and used through the semantic layer. The pipeline matters and is largely a solved problem. The semantic model is where the measure definitions, the hierarchy versions and the access rules live, which means it is where the arguments either get settled or get distributed to every consumer.
| Layer | What belongs there |
|---|---|
| Source integration | Syndicated data with vintage and methodology version, CRM, ERP, finance, supply chain, patient services |
| Raw retention | Source form kept as delivered, so a vendor restatement can be reconciled against what you had |
| Conformed dimensions | Territory, product, customer, payer and organization hierarchies held with effective dates |
| Measure logic | Certified calculations, one official definition each, variants explicitly named |
| Semantic model | The consumption contract: measures, hierarchies, descriptions and access rules in one place |
| Access enforcement | Role, territory and contract based restrictions resolved at query time rather than per report |
| Consumption | Executive dashboards, operational reporting, self-service datasets, forecasting inputs, exports |
If the measure logic lives in the reports, you do not have a semantic model. A useful diagnostic: pick an important measure and count how many places its calculation exists. If it is written into individual reports, workbooks and extracts, then a definition change requires finding and editing all of them, which means in practice they will drift and already have. A semantic model exists when there is one place the calculation lives, one place to change it, and everything downstream inherits that change. Most organizations that believe they have a governed model have a well-built warehouse with the logic scattered above it, and the symptom is that nobody can say with confidence how many versions of a measure are in circulation.
Commercial analytics is often assumed to sit outside the regulated estate, and parts of it do not. Data about healthcare professionals carries privacy obligations and in some jurisdictions explicit opt-out mechanisms. Syndicated data arrives under contract terms that restrict what may be shown, to whom, and at what grain. Patient services data is health information. Some commercial outputs feed regulated reporting. Which of these applies to a given system, and what validation is required, is determined by your legal, privacy, regulatory and quality functions. Our role is to build so that the controls they specify are enforceable.
Frameworks where they apply
- GxP and GAMP 5 where a commercial or operational system supports a regulated activity
- FDA 21 CFR Part 11 and EU Annex 11 for electronic records and signatures where applicable
- Aggregate spend and transparency reporting obligations where commercial data feeds them
- Applicability, system classification and validation strategy determined by your quality and regulatory functions
Privacy
- HIPAA where the organization handles protected health information
- GDPR and equivalent regimes for personal data of professionals and patients
- HCP data privacy, including opt-out status honoured in every downstream view
- Patient services data held within the consent given for it
Contract and access
- Syndicated data vendor terms on permitted use, grain and redistribution
- Role, territory and contract based access resolved at query time
- Separation between commercial, clinical and patient services data enforced in the platform
- Export and download controls, because an export leaves your access model behind
Integrity
- Lineage from a reported figure back to the source and vintage it came from
- Audit trail of changes to certified measure definitions and to access rights
- Controlled change for definitions, hierarchies and models that feed decisions
- Validation scoped to intended use for systems your quality function classifies as regulated
Commercial analytics environments degrade in ways that do not produce errors. A vendor restates history. A territory realignment lands. A CRM administrator adds a picklist value. A product hierarchy changes. The pipeline runs green through all of it and delivers figures that have quietly stopped meaning what they meant. The monitoring that matters here watches the numbers, not the jobs.
| Failure | How it presents |
|---|---|
| A syndicated vendor restates prior periods | History moves, your warehouse and the vendor disagree, and nobody changed anything |
| A territory realignment takes effect | Rep level trends break and year on year comparisons silently compare different prescribers |
| A CRM picklist or field changes | An activity category stops being counted and the volume looks like a behaviour change |
| Identity match rates decay | Unmatched activity and prescribing grow, and the covered portion is no longer representative |
| Channel inventory moves | Shipment data reads as a demand surge and the forecast follows it |
| A measure is redefined in one report | Two versions of a figure circulate and both are defended as correct |
| Access rights go stale after a role change | Somebody retains territory or contract scoped access they should no longer have |
| A refresh completes on partial data | Totals are plausible, a source arrived short, and the shortfall is within normal variation |
| Commercial sales are read as recognized revenue | Two correct figures disagree, and the gross to net difference gets investigated as an error |
| A certified figure is exported and recalculated | The spreadsheet version arrives at the meeting and the access model was left behind |
Commercial analytics programmes are usually measured on what was delivered: dashboards built, sources integrated, users onboarded. Those are activity measures. The outcomes that matter are whether decisions get made faster, whether the numbers are disputed, and whether the organization can explain what each figure is evidence of.
| Outcome | How to tell |
|---|---|
| Commercial visibility improved | The weekly commercial decision is made from one view rather than from four assembled files |
| Numbers stopped being disputed | Two functions presenting the same quarter now present the same figure |
| Sales and marketing performance better understood | Investment questions answered with stated evidence and named limitations rather than one figure |
| Operational efficiency strengthened | Manufacturing, supply and inventory decisions read from the same certified measures as commercial |
| Forecast accuracy improved | Error known by product and horizon, tracked against snapshotted forecasts, and trending down |
| Cost reduced | Analytics consumption cost per decision falling, and retired products no longer maintained |
| Decisions became data driven in practice | Each certified view has a named owner, a stated decision and evidence it is used in that decision |
We work with pharmaceutical, biotechnology and research organizations on the commercial and operational analytics layer: syndicated, CRM, ERP, finance and supply chain data integrated into one governed model, with measure definitions settled, hierarchy history retained, access enforced where it belongs, and each view tied to a decision somebody actually makes.
CaliberFocus builds commercial and operational analytics for pharmaceutical, biotechnology and research organizations that leadership can defend. We settle the measure definitions before the model is built, keep territory and product history so trends can be restated, carry the vintage and limits of syndicated data with the data, and enforce privacy and vendor terms in the semantic model rather than in individual reports.
- One certified definition and owner for every measure leadership acts on
- Syndicated, CRM, ERP and supply chain data in one governed model
- Access, opt-outs and vendor terms enforced in the model
- Forecasts and attribution presented with their assumptions and ranges
Security & Compliance
